Background
Paul Lisenby served as Global Head of Product Development for Gyrus ACMI, Inc., Olympus Corporation of the Americas, and Olympus America, Inc., collectively referred to as Olympus. Olympus sells medical devices to the federal government and to healthcare providers receiving Medicare and Medicaid reimbursements. In early 2024, Lisenby identified alleged systemic deficiencies in Olympus’s product design, quality controls, testing, and compliance with FDA requirements, including problems involving the Quick-Clip Pro 2 device.
Over approximately two weeks, Lisenby raised those concerns with several Olympus executives and committees, emphasizing FDA compliance, product safety, and patient harm and proposing a design methodology to address the problems. Olympus eliminated his position the day after his final reported meeting. Lisenby sued under the False Claims Act’s anti-retaliation provision and state whistleblower laws. The district court dismissed the amended complaint with prejudice because it did not connect his reports of regulatory violations to actual or anticipated false claims for government payment. Lisenby appealed only the dismissal of his FCA retaliation claim.
The Court’s Holding
The Third Circuit affirmed. Addressing two questions of first impression in the circuit, the court first held that an FCA retaliation claim is governed by Federal Rule of Civil Procedure 8(a), not Rule 9(b)’s heightened particularity requirement. Unlike a substantive FCA fraud claim, a retaliation claim concerns discrimination against an employee for protected conduct and therefore does not itself allege fraud.
The court also held that conduct qualifies as protected “other efforts” under 31 U.S.C. § 3730(h)(1) when the employee acts in good faith based on an objectively reasonable belief that the employer is violating or will violate the FCA. The employee’s efforts must have a nexus to the submission of false or fraudulent claims for federal payment; reporting statutory or regulatory noncompliance alone is insufficient.
Lisenby’s amended complaint did not allege that he believed Olympus had submitted or would submit false claims for government payment. His reported concerns involved FDA violations, deficient testing, product safety, and patient harm. Olympus’s federal sales and receipt of federal funds did not supply the missing connection, and the implied-false-certification theory could not cure the absence of allegations about Lisenby’s own belief. Because he failed to plead protected conduct, the court did not decide whether any such belief would have been objectively reasonable or whether Olympus had notice of FCA-protected activity.
Key Takeaways
- FCA retaliation claims are subject to Rule 8(a)’s ordinary notice-pleading standard, not Rule 9(b)’s fraud-particularity requirement.
- An employee invoking the “other efforts” prong must have a good-faith, objectively reasonable belief that the employer is committing or will commit an FCA violation.
- Reports of regulatory noncompliance, safety defects, or patient harm are not protected under the FCA unless they are connected to false or fraudulent claims for federal payment.
Why It Matters
The precedential decision establishes the Third Circuit’s standard for protected conduct under the FCA’s post-amendment “other efforts” provision. Although the court described the objectively reasonable belief requirement as a relatively low bar designed to protect preventive whistleblowing, employees must still allege facts linking their efforts to suspected fraud on the federal government.
For employers and whistleblower counsel, the decision draws a consequential distinction between complaints about regulatory compliance and conduct protected by the FCA. No particular terminology is required, but a retaliation complaint must plausibly allege that the employee believed the reported misconduct involved actual or anticipated false claims for federal payment.